Moderna Announces 94.5 Percent Effectiveness in COVID Vaccine

US pharma giant Moderna's COVID vaccine candidate has shown more than 94.5 percent effectiveness in preliminary data from its ongoing study.

Moderna Inc has claimed that its experimental vaccine was 94.5 percent effective in preventing coronavirus based on data from a late-stage clinical trial, becoming the second US company in a week to report results that surpass expectations.

Pfizer Inc had announced 90 percent efficacy exactly a week ago. Taken together, these two vaccines are firmly on course to seek emergency use authorization from the US Food and Drug Administration if results hold out in final study results due soon.

COVID Vaccines Of China Could be Ready by November
The general population in China may start getting access to the locally prepared COVID-19 vaccines from November or December.

‘The US has the world's highest known number of coronavirus cases and deaths, with more than 11 million infections and approximately 250,000 deaths. ’

"This is a pivotal moment in the development of our Covid-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible," said Stephane Bancel, Chief Executive Officer at Moderna.

"All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent the Covid-19 disease, including severe disease," Bancel added.

Anthony Fauci from Trump's coronavirus task force is optimistic that these early vaccines will change the course of "everything we do" over the next few months.

Health Experts React To Russian Covid Vaccine Cautiously
Cautiously after the news of Russia registering the world's first Covid-19 vaccine, Indian health experts stressed that it would be too early to say if it is safe or not as adequate testing didn't take place.

Pfizer's final results are due in the third week of November - around the time of the Thanksgiving holiday.

Covid cases in the US crossed 11 million by November 15, with the latest 1 million coming in a week. The country's death toll is the world's highest - more than 246,000 at last count.

COVID Vaccine: Infections Seen Among Sputnik Trial Subjects
There have been instances of infection among volunteers of Sputnik V trials, the world's first registered vaccine against Covid-19 virus, according to a top official of the developer of Russian vaccine.

Roughly 20 million people could be vaccinated against the coronavirus in December, the chief of the Donald Trump administration's vaccine coordination program has indicated. Anywhere from 25 to 30 million people could be vaccinated each month after that.

The US is working with a portfolio of six vaccines, using three different platform technologies and two candidates from each platform: Messenger RNA, live viral vectors, and recombinant protein.

Clinical Trials of Covid Vaccine Begins In India
For India's first indigenous Covid-19 vaccine, two volunteers were given its first dose at the Nizam's Institute of Medical Sciences (NIMS) on Monday.

Pfizer and Moderna's vaccines use the messenger RNA platform, Johnson and Johnson, and AstraZeneca, in partnership with Oxford University, is on the live vector path while Novavax and Sanofi/GlaxoSmithKline are building out their vaccine candidates on the recombinant protein platform.

The study, known as the COVE study, enrolled more than 30,000 participants in the US and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services.

The company said it remains on track to manufacture 500 million to 1 billion doses globally in 2021.

Source-IANS